arrow
A

Annapaola Callegaro

irccs ca' granda - ospedale maggiore policlinico
H指数:15
被引数:897

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mathematical modeling of HDV RNA, HBsAg, and ALT kinetics in patients with compensated cirrhosis: Insights from 96 Weeks of bulevirtide monotherapy

compensated肝硬变患者中HDV RNA、HBsAg和ALT动力学的数学建模:96周bulevirtide单药治疗的启示

2026-08-010
PRE
Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity

10年来血液病患者的病毒性呼吸道感染:流行病学及其对疾病严重程度的影响

2025-10-010
PRE
Multicenter Cross-sectional Study on the Epidemiology of Human Metapneumovirus in Italy, 2022-2024, With a Focus on Adults Over 50 Years of Age

意大利2022–2024年人甲型肺炎病毒流行病学的多中心横断面研究,重点关注50岁以上成年人

2025-07-154
PRE
Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV

比较接受布来韦尔替(bulevirtide)治疗与未治疗的丁型肝炎病毒(HDV)患者血浆中HDV RNA定量方法的比较

2025-03-010
OAAI
Differential patterns of HBV RNA and HBcrAg levels in a large european cross-sectional study of untreated patients with chronic Hepatitis Delta
2025-03-010
PRE
Genomic characterization of Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) strains circulating in three university hospitals in Northern Italy over three years

三年来在意大利北部三所大学医院中流行的产生肺炎克雷伯菌碳青霉烯酶的肺炎克雷伯菌 (kpc-kp) 菌株的基因组特征

2024-07-032
OAAI
Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021
2023-11-050
OA
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype

根据耐药突变和病毒亚型,doluteggravir与Darunavir在抗逆转录病毒一线治疗方案中的疗效

2023-03-161
OAAI
Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020
2022-04-067
OAAI
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021

2020年10月至2021年3月在意大利流通的SARS-CoV-2变种

2021-08-1437
OAAI